{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-006773","form_type":"8-K","ticker":"ENSC","cik":"0001716947","company_name":"Ensysce Biosciences, Inc.","filed_at":"2024-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.230968+00:00","generated_at":"2026-06-06T02:28:14.667861+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ensysce raises $4.7M via warrant exercise, issues new warrants at $1.06","bullets":["Gross proceeds ~$4.7M from cash exercise of 3,601,752 existing warrants at reduced price $1.31 per share.","Issues unregistered Series A/B warrants for 7,203,504 shares at $1.06; Series A expire 18 months, Series B May 2028.","Net proceeds for Phase 3 prep of PF614, debt repayment (Oct/Nov 2023), and general corporate.","Placement agent H.C. Wainwright gets $200k fee and 252,123 warrants at $1.6375.","Waiver from Oct 2023 SPA requires full note repayment with premium post-closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-006773","json":"https://secwatch.observer/filing/0001493152-24-006773.json","markdown":"https://secwatch.observer/filing/0001493152-24-006773.md","text":"https://secwatch.observer/filing/0001493152-24-006773.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716947/000149315224006773/0001493152-24-006773-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716947/000149315224006773/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T02:28:14.667861+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"627289b8348f68870892955a8425bde90cad5034","claim":"Ensysce Biosciences, Inc. entered into Inducement Letter with certain holders valued at approximately $4.7 million (effective 2024-02-12).","evidence_excerpt":"On February 12, 2024, Ensysce Biosciences, Inc., a Delaware corporation (the “ Company ”), entered into an inducement offer letter agreement (the “ Inducement Letter ”) with certain holders (the “ Holders ”) of certain of its existing warrants to purchase up to an aggregate of 3,601,752 shares of the Company’s common stock, $0.0001 par value (the “ Common Stock ”), issued to the Holders on May 12, 2023 and having an exercise price of $3.637 per share (the “ Existing Warrants ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315224006773/0001493152-24-006773-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain holders"},{"label":"Value","value":"approximately $4.7 million"},{"label":"Effective","value":"2024-02-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}